TELCYTA®
(TLK286) in Combination |
|
|
Clinical Indication |
|
|
Research / Preclinical |
|
Phase 1 |
|
Phase 2 |
|
Phase 3 |
|
|
|
Carboplatin
(Ovarian) |
|
|
 |
|
|
|
|
|
 |
|
|
|
| Carboplatin
(Ovarian) |
|
|
|
|
|
|
|
|
 |
|
|
| Liposomal
Doxorubicin (Ovarian) |
|
|
|
|
|
|
|
|
|
|
|
| Docetaxel
(NSCLC) |
|
|
|
|
|
|
|
|
|
|
|
| Cisplatin
(NSCLC) |
|
|
|
|
|
|
|
|
|
|
|
| Carboplatin & Paclitaxel
(NSCLC) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TELCYTA®
(TLK286) Monotherapy |
|
|
Clinical Indication |
|
|
Research / Preclinical |
|
Phase 1 |
|
Phase 2 |
|
Phase 3 |
|
|
|
Ovarian
Cancer |
|
|
 |
|
|
|
|
|
 |
|
|
|
Non-Small
Cell
Lung Cancer (NSCLC) |
|
|
|
|
|
|
|
|
 |
|
|
| Colorectal
Cancer |
|
|
|
|
|
|
|
|
 |
|
|
| Breast
Cancer |
|
|
|
|
|
|
|
|
|
